| Literature DB >> 26413060 |
Dalia Moemen1, Doaa Tawfeek1, Wafaa Badawy1.
Abstract
Vancomycin resistant Enterococcus faecium (VREF) ia an emerging and challenging nosocomial pathogen. This study aimed to determine the prevalence, risk factors and clonal relationships between different VREF isolates in the intensive care units (ICUs) of the university hospitals in our geographic location. This prospective study was conducted from July, 2012 until September, 2013 on 781 patients who were admitted to the ICUs of the Mansoura University Hospitals (MUHs), and fulfilled the healthcare-associated infection (HAI) criteria. Susceptibility testing was determined using the disk diffusion method. The clonal relationships were evaluated with pulsed field gel electrophoresis (PFGE). Out of 52 E. faecium isolates, 12 (23.1%) were vancomycin resistant. The significant risk factors for the VREF infections were: transfer to the ICU from a ward, renal failure, an extended ICU stay and use of third-generation cephalosporins, gentamicin, or ciprofloxacin. PFGE with the 12 isolates showed 9 different patterns; 3 belonged to the same pulsotype and another 2 carried a second pulsotypes. The similar pulsotypes isolates were isolated from ICUs of one hospital (EICUs); however, all of the isolates from the other ICUs had different patterns. Infection control policy, in conjunction with antibiotic stewardship, is important to combat VREF transmission in these high-risk patients.Entities:
Keywords: Enterococcus faecium; ICU; PFGE; risk factors; vancomycin
Mesh:
Substances:
Year: 2015 PMID: 26413060 PMCID: PMC4568866 DOI: 10.1590/S1517-838246320140403
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
ICU-acquired VREF infection risk factors
| Factor | Patients with
| p- value | Odds ratio | |||
|---|---|---|---|---|---|---|
|
| ||||||
| VREF n = 12 | VSEF n = 40 | |||||
|
|
| |||||
| No. | (%) | No. | (%) | |||
| Sex (male): | 7 | 58.3 | 25 | 62.5 | 0.8 | 0.84 |
| Diabetes mellitus | 3 | 25.0 | 7 | 17.5 | 0.7 | 1.6 |
| Neutropenia | 4 | 33.3 | 10 | 25.0 | 0.7 | 1.5 |
| Neoplastic disease | 5 | 41.7 | 16 | 40.0 | 0.9 | 1.1 |
| Transfer to the ICU from a ward | 8 | 66.6 | 12 | 30.0 |
| 4.7 |
| Surgery | 4 | 33.3 | 14 | 35.0 | 1 | 0.9 |
| Immunosuppressive drugs | 5 | 41.7 | 11 | 27.5 | 0.4 | 1.9 |
| Prior antibiotic treatment | 10 | 83.3 | 28 | 70.0 | 0.5 | 2.1 |
| Organ failure: | ||||||
| Respiratory | 3 | 25 | 6 | 15 | 0.4 | 1.9 |
| Cardiac | 2 | 16.7 | 7 | 17.5 | 1 | 0.9 |
| Renal | 5 | 41.7 | 3 | 7.5 |
| 8.8 |
| Neurologic | 1 | 8.3 | 6 | 15.0 | 1 | 0.5 |
| Liver | 3 | 25 | 5 | 12.5 | 0.4 | 2.3 |
| During ICU hospitalization: | ||||||
| Intravascular catheter | 12 | 100 | 36 | 90 | 0.6 | - |
| Urinary catheter | 12 | 100 | 37 | 92.5 | 1 | - |
| Mechanical ventilation | 12 | 100 | 37 | 92.5 | 1 | - |
|
| ||||||
| ICU stay duration (days) | 12 ± 5.51 | 9.23 ± 4.86 |
| 0.47–5.06 | ||
Significant, p-value ≤ 0.05;
ICU, intensive care unit.
Antibiotic use amongst the study patients during their ICU stays
| Factor | Patients with
| p-value | Odds ratio | |||
|---|---|---|---|---|---|---|
|
| ||||||
| VREF n = 12 | VSEF n = 40 | |||||
|
|
| |||||
| No. | (%) | No. | (%) | |||
| Antibiotic treatment duration, days | 16 ± 11 | 5 ± 6 | <
| 8.09–13.91 | ||
| Vancomycin use | 5 | 41.7 | 12 | 30.0 | 0.45 | 1.66 |
| Extended-spectrum penicillin use | 7 | 58.3 | 19 | 47.5 | 0.5 | 1.6 |
| Fluoroquinolone use | 9 | 75 | 16 | 40.0 | 1 | 0.8 |
| Carbapenem use | 3 | 25.0 | 12 | 30.0 | 1 | 0.8 |
| Aminoglycoside use | 6 | 50.0 | 8 | 20.0 |
| 4 |
| First generation cephalosporin use | 2 | 16.7 | 18 | 45.0 | 0.09 | 0.2 |
| Second generation cephalosporin use | 2 | 16.7 | 15 | 37.5 | 0.3 | 0.3 |
| Third generation cephalosporin use | 6 | 50.0 | 6 | 15.0 |
| 5.7 |
Significant, p-value ≤ 0.05;
highly significant, p-value ≤ 0.001.
Figure 1SmaI restriction endonuclease patterns obtained by PFGE: Lane M marker; lane 1, patient 1 (SMICU); lanes 2, 3 and 4 (EICUs); lane 5, (PICU); lanes 6 and 7, (EICUs); lane 8, (PICU); lane 9, (SMICU); lane 10, (SMICU); lane 11, (SMICU); lane 12, (EICU)